Eiger To Discontinue Peginterferon Lambda Trial In CHD Patients; Stock Down In Premarket
Eiger BioPharmaceuticals, Inc. (EIGR), a commercial-stage biopharmaceutical company focused on rare metabolic diseases, Wednesday said it has decided to discontinue the Phase 3 LIMT-2 study of peginterferon lambda in patients […]
» Read more